Summary
In a significant market movement during July 2020, Freeline Therapeutics was the subject of a vc funding. The transaction achieved a gross valuation of £64,233,784. Leading the round was Eventide Asset Management, Wellington Management, Novo Holdings.
This transaction was brokered by an undisclosed advisor. The deal reflects ongoing market confidence within its sector.
Lead Investor / Acquirer
Eventide Asset Management
Lead Investor / Acquirer
Wellington Management
Lead Investor / Acquirer
Novo Holdings
Advising Broker
Undisclosed Firm
Related Deals in Healthcare & Biotech
Series C prioritisedOriginal Source
This funding round is sourced from the Tech.eu Funding Explorer. View the full record, investors, and citations there.
View on Tech.eu Funding ExplorerFunding data via Tech.eu Funding Explorer, licensed under CC BY 4.0. See our methodology.
AI Insight Lenses
ProAI-generated analysis from four professional perspectives. Powered by PE Deals.
Sign in to unlock AI Lenses
Sign in